Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, made an expensive and gutsy move into the cutting edge of cancer treatment this morning, spending $11.9 billion in cash to buy Kite Pharma, the developer of a treatment that attacks tumors by genetically modifying patients’ own white blood cells.

Continue reading on Forbes